Candriam S.C.A. Sells 56,053 Shares of IDEXX Laboratories, Inc. $IDXX

Candriam S.C.A. reduced its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 70.9% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 22,975 shares of the company’s stock after selling 56,053 shares during the quarter. Candriam S.C.A.’s holdings in IDEXX Laboratories were worth $14,678,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. STF Management LP lifted its stake in shares of IDEXX Laboratories by 1.3% in the 2nd quarter. STF Management LP now owns 1,240 shares of the company’s stock valued at $665,000 after purchasing an additional 16 shares during the period. Clearstead Trust LLC grew its stake in shares of IDEXX Laboratories by 1.1% during the second quarter. Clearstead Trust LLC now owns 1,515 shares of the company’s stock worth $813,000 after purchasing an additional 16 shares during the period. MassMutual Private Wealth & Trust FSB increased its holdings in IDEXX Laboratories by 4.4% in the third quarter. MassMutual Private Wealth & Trust FSB now owns 380 shares of the company’s stock valued at $243,000 after purchasing an additional 16 shares during the last quarter. Moss Adams Wealth Advisors LLC increased its holdings in IDEXX Laboratories by 3.3% in the third quarter. Moss Adams Wealth Advisors LLC now owns 528 shares of the company’s stock valued at $337,000 after purchasing an additional 17 shares during the last quarter. Finally, Stratos Wealth Partners LTD. lifted its stake in IDEXX Laboratories by 1.7% in the second quarter. Stratos Wealth Partners LTD. now owns 1,051 shares of the company’s stock valued at $564,000 after buying an additional 18 shares during the period. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $639.79 on Tuesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $769.98. The firm’s 50 day moving average price is $691.95 and its two-hundred day moving average price is $666.49. The firm has a market cap of $51.09 billion, a P/E ratio of 48.95, a PEG ratio of 3.93 and a beta of 1.67.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, February 2nd. The company reported $3.08 EPS for the quarter, topping analysts’ consensus estimates of $2.93 by $0.15. The business had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The firm’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period last year, the business posted $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on IDXX shares. Jefferies Financial Group restated a “buy” rating and set a $830.00 target price on shares of IDEXX Laboratories in a research report on Tuesday, November 4th. Leerink Partners set a $785.00 price objective on shares of IDEXX Laboratories in a research note on Monday, November 3rd. Barclays lowered their target price on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research note on Thursday. Wall Street Zen upgraded shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, Morgan Stanley lifted their price target on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Seven analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $783.33.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.